A Randomized, Open-Label, Parallel-Arm, Noninferiority Comparison of the Effects of Two Doses of LY2189265 and Insulin Glargine on Glycemic Control in Patients with Type 2 Diabetes on Stable Doses of Metformin and Glimepiride (AWARD-2: Assessment of Weekly AdministRation of LY2189265 in Diabetes-2)

Trial Profile

A Randomized, Open-Label, Parallel-Arm, Noninferiority Comparison of the Effects of Two Doses of LY2189265 and Insulin Glargine on Glycemic Control in Patients with Type 2 Diabetes on Stable Doses of Metformin and Glimepiride (AWARD-2: Assessment of Weekly AdministRation of LY2189265 in Diabetes-2)

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jun 2018

At a glance

  • Drugs Dulaglutide (Primary) ; Glimepiride; Insulin glargine; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms AWARD-2
  • Sponsors Eli Lilly
  • Most Recent Events

    • 26 Jun 2018 Results of a post-hoc analysis assessing the efficacy of Dulaglutide vs. Insulin Glargine in patients with T2D with different glycaemic patterns at baseline, presented at the 78th Annual Scientific Sessions of the American Diabetes Association
    • 08 Dec 2017 Results of post hoc analysis assessing effect of dulaglutide 1.5 mg and 0.75 mg versus insulin glargine on composite endpoints consisting of the percentages of elderly patients achieving HbA1c less than 7.5% presented at the 2017 Congress of the International Diabetes Federation
    • 15 Sep 2017 Results of pooled post-hoc analysis of AWARD-2,4 and 5 , presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top